Indian pharmaceutical company Bharat Biotech has said that a booster shot of its Covaxin COVID-19 vaccine administered six months after the last of two doses neutralises both the Omicron and Delta variants of COVID-19, Reuters news agency reported on Wednesday.
This study was conducted at the Emory Vaccine Centre in Atlanta, US, based on blood serum collected from 13 individuals, 28 days after their booster shot. It was sponsored by Bharat Biotech's partner Ocugen Inc (Nasdaq:OCGN).
In a statement, Bharat Biotech said: "The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant. More than 90% of all individuals boosted with Covaxin showed neutralising antibodies."
Covaxin, India's first domestically developed COVID-19 vaccine, received a WHO emergency-use listing late in 2021.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine